We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.25 | 0.32% | 77.43 | 77.02 | 77.50 | 77.49 | 77.151 | 77.23 | 2,565,594 | 21:00:04 |
From May 2021 to May 2024
By Sabela Ojea
AstraZeneca PLC said Monday that the Calquence drug-inhibitor showed improvements in atrial fibrillation when compared with ibrutinib in previously treated adult patients with chronic lymphocytic leukemia.
The pharmaceutical giant said Calquence also proved to give favorable tolerability at four years.
The company said these final results of Calquence come from the head-to-head elevate-rr phase 3 trial.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
June 07, 2021 02:30 ET (06:30 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
